Open Government Portal

The purpose of this Notice of Amendment is to notify that Health Canada has revised the listing for naproxen on the Prescription Drug List (PDL). Only the Human part of the PDL was revised; the listing for Veterinary use will remain unchanged.

The purpose of this Notice of Amendment is to notify that Health Canada is clarifying the nicotine qualifier entry on the PDL. Only the qualifier for human use is being revised.

The purpose of this Notice of Amendment is to notify that Health Canada will switch certain uses of Polymyxin B to prescription status for veterinary use by adding it to the Veterinary Prescription Drug List (PDL). The Human listing for Polymyxin B of the PDL remains unchanged.

The purpose of this Notice of Amendment is to notify about the addition of sotrovimab to the Prescription Drug List (PDL) for human and veterinary use.

The purpose of this Notice of Intent to Amend is to notify that, as a result of consultation, Health Canada will revise the listing for Adrenocortical hormones on the Prescription Drug List (PDL) to exempt Triamcinolone acetonide.

The purpose of this Notice of Amendment is to notify that Health Canada has revised the listing of Vitamin D on the Prescription Drug List (PDL) to allow non-prescription status for products a) containing up to 62.5 µg or 2,500 International Units (IU)/dosage form for oral use; or b) with a maximum recommended daily oral intake of 2,500 IU. Only the Human part of the PDL was revised.

The purpose of this Notice of Amendment is to notify about the additions of:
- Strain Russian BCG-I to the "including" column of the |Bacillus Calmette-Guérin (BCG)" entry on the Prescription Drug List for human and veterinary use,
- Bedinvetmab to the PDL for veterinary use, and
- Binimetinib, Brillant Blue G, encorafenib, eptinezumab, mecasermin, onasemnogene abeparvovec, ponesimod, ranolazine, triheptanoin and zanubrutinib to the PDL for human and veterinary use.

The purpose of this Notice of Amendment is to notify about the additions of the following medicinal ingredients on the Prescription Drug List (PDL) for human and veterinary use: Brexucabtagene autoleucel; Idecabtagene vicleucel; Pitolisant; Risdiplam; Selpercatinib; Solriamfetol; Tepotinib; Tildrakizumab; Trastuzumab; deruxtecan.

The purpose of this Notice of Amendment is to notify about the additions of: Elexacaftor, Inclisiran, Ospemifene, Pralsetinib and Tafasitamab to the Prescription Drug List (PDL) for human and veterinary use, and Frunevetmab to the PDL for veterinary use.

The purpose of this Notice of Amendment is to notify of the addition of the following medicinal ingredients on the Prescription Drug List (PDL) for human and veterinary use: Infigratinib or its salts, Lurbinectedin or its salts or derivatives, Pemigatinib or its salts, Propylthiouracil or its salts, Sacituzumab govitecan, and Sotorasib.